vs

Side-by-side financial comparison of Builders FirstSource (BLDR) and Zoetis (ZTS). Click either name above to swap in a different company.

Builders FirstSource is the larger business by last-quarter revenue ($3.3B vs $2.3B, roughly 1.5× Zoetis). Zoetis runs the higher net margin — 26.6% vs 2.9%, a 23.6% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (2.9% vs -10.1%). Over the past eight quarters, Zoetis's revenue compounded faster (-2.1% CAGR vs -14.1%).

Builders FirstSource, Inc. is a Fortune 500 company that is a manufacturer and supplier of building materials. The company is headquartered in Irving, Texas, and is the largest supplier of building products, prefabricated components and value-added services in the US. Builders FirstSource employs over 15,000 people throughout the USA. They serve new residential construction, repair and remodeling professionals. The company was incorporated in March 1998.

Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...

BLDR vs ZTS — Head-to-Head

Bigger by revenue
BLDR
BLDR
1.5× larger
BLDR
$3.3B
$2.3B
ZTS
Growing faster (revenue YoY)
ZTS
ZTS
+13.0% gap
ZTS
2.9%
-10.1%
BLDR
Higher net margin
ZTS
ZTS
23.6% more per $
ZTS
26.6%
2.9%
BLDR
Faster 2-yr revenue CAGR
ZTS
ZTS
Annualised
ZTS
-2.1%
-14.1%
BLDR

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BLDR
BLDR
ZTS
ZTS
Revenue
$3.3B
$2.3B
Net Profit
$96.3M
$601.0M
Gross Margin
28.3%
71.7%
Operating Margin
0.5%
Net Margin
2.9%
26.6%
Revenue YoY
-10.1%
2.9%
Net Profit YoY
-0.2%
EPS (diluted)
$0.27
$1.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLDR
BLDR
ZTS
ZTS
Q1 26
$3.3B
$2.3B
Q4 25
$3.4B
$2.4B
Q3 25
$3.9B
$2.4B
Q2 25
$4.2B
$2.5B
Q1 25
$3.7B
$2.2B
Q4 24
$3.8B
$2.3B
Q3 24
$4.2B
$2.4B
Q2 24
$4.5B
$2.4B
Net Profit
BLDR
BLDR
ZTS
ZTS
Q1 26
$96.3M
$601.0M
Q4 25
$31.5M
$603.0M
Q3 25
$122.4M
$721.0M
Q2 25
$185.0M
$718.0M
Q1 25
$96.3M
$631.0M
Q4 24
$190.2M
$581.0M
Q3 24
$284.8M
$682.0M
Q2 24
$344.1M
$624.0M
Gross Margin
BLDR
BLDR
ZTS
ZTS
Q1 26
28.3%
71.7%
Q4 25
29.8%
70.2%
Q3 25
30.4%
71.5%
Q2 25
30.7%
73.6%
Q1 25
30.5%
72.0%
Q4 24
32.3%
69.5%
Q3 24
32.8%
70.6%
Q2 24
32.8%
71.7%
Operating Margin
BLDR
BLDR
ZTS
ZTS
Q1 26
0.5%
Q4 25
1.8%
31.9%
Q3 25
5.8%
37.0%
Q2 25
7.4%
36.7%
Q1 25
5.0%
36.5%
Q4 24
8.0%
31.6%
Q3 24
10.1%
36.6%
Q2 24
11.0%
33.0%
Net Margin
BLDR
BLDR
ZTS
ZTS
Q1 26
2.9%
26.6%
Q4 25
0.9%
25.3%
Q3 25
3.1%
30.0%
Q2 25
4.4%
29.2%
Q1 25
2.6%
28.4%
Q4 24
5.0%
25.1%
Q3 24
6.7%
28.6%
Q2 24
7.7%
26.4%
EPS (diluted)
BLDR
BLDR
ZTS
ZTS
Q1 26
$0.27
$1.42
Q4 25
$0.29
$1.37
Q3 25
$1.10
$1.63
Q2 25
$1.66
$1.61
Q1 25
$0.84
$1.41
Q4 24
$1.65
$1.29
Q3 24
$2.44
$1.50
Q2 24
$2.87
$1.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLDR
BLDR
ZTS
ZTS
Cash + ST InvestmentsLiquidity on hand
$98.3M
Total DebtLower is stronger
$24.3M
Stockholders' EquityBook value
Total Assets
$11.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLDR
BLDR
ZTS
ZTS
Q1 26
$98.3M
Q4 25
$181.8M
Q3 25
$296.2M
$2.1B
Q2 25
$87.0M
$1.4B
Q1 25
$115.4M
$1.7B
Q4 24
$153.6M
$2.0B
Q3 24
$328.1M
$1.7B
Q2 24
$75.6M
$1.6B
Total Debt
BLDR
BLDR
ZTS
ZTS
Q1 26
$24.3M
Q4 25
$4.4B
Q3 25
$4.4B
Q2 25
$4.7B
Q1 25
$4.5B
Q4 24
$3.7B
Q3 24
$3.7B
Q2 24
$3.8B
Stockholders' Equity
BLDR
BLDR
ZTS
ZTS
Q1 26
Q4 25
$4.4B
$3.3B
Q3 25
$4.3B
$5.4B
Q2 25
$4.2B
$5.0B
Q1 25
$4.4B
$4.7B
Q4 24
$4.3B
$4.8B
Q3 24
$4.4B
$5.2B
Q2 24
$4.3B
$5.0B
Total Assets
BLDR
BLDR
ZTS
ZTS
Q1 26
$11.3B
Q4 25
$11.2B
$15.5B
Q3 25
$11.4B
$15.2B
Q2 25
$11.5B
$14.5B
Q1 25
$11.4B
$14.1B
Q4 24
$10.6B
$14.2B
Q3 24
$10.9B
$14.4B
Q2 24
$10.7B
$14.2B
Debt / Equity
BLDR
BLDR
ZTS
ZTS
Q1 26
Q4 25
1.02×
Q3 25
1.03×
Q2 25
1.12×
Q1 25
1.02×
Q4 24
0.86×
Q3 24
0.83×
Q2 24
0.88×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLDR
BLDR
ZTS
ZTS
Operating Cash FlowLast quarter
$87.5M
Free Cash FlowOCF − Capex
$42.7M
FCF MarginFCF / Revenue
1.3%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.91×
TTM Free Cash FlowTrailing 4 quarters
$863.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLDR
BLDR
ZTS
ZTS
Q1 26
$87.5M
Q4 25
$194.8M
$893.0M
Q3 25
$547.7M
$938.0M
Q2 25
$341.0M
$486.0M
Q1 25
$132.3M
$587.0M
Q4 24
$373.5M
$905.0M
Q3 24
$730.0M
$951.0M
Q2 24
$452.1M
$502.0M
Free Cash Flow
BLDR
BLDR
ZTS
ZTS
Q1 26
$42.7M
Q4 25
$106.7M
$732.0M
Q3 25
$461.9M
$805.0M
Q2 25
$252.3M
$308.0M
Q1 25
$32.4M
$438.0M
Q4 24
$273.8M
$689.0M
Q3 24
$630.4M
$784.0M
Q2 24
$364.0M
$370.0M
FCF Margin
BLDR
BLDR
ZTS
ZTS
Q1 26
1.3%
Q4 25
3.2%
30.7%
Q3 25
11.7%
33.5%
Q2 25
6.0%
12.5%
Q1 25
0.9%
19.7%
Q4 24
7.2%
29.7%
Q3 24
14.9%
32.8%
Q2 24
8.2%
15.7%
Capex Intensity
BLDR
BLDR
ZTS
ZTS
Q1 26
Q4 25
2.6%
6.7%
Q3 25
2.2%
5.5%
Q2 25
2.1%
7.2%
Q1 25
2.7%
6.7%
Q4 24
2.6%
9.3%
Q3 24
2.4%
7.0%
Q2 24
2.0%
5.6%
Cash Conversion
BLDR
BLDR
ZTS
ZTS
Q1 26
0.91×
Q4 25
6.19×
1.48×
Q3 25
4.48×
1.30×
Q2 25
1.84×
0.68×
Q1 25
1.37×
0.93×
Q4 24
1.96×
1.56×
Q3 24
2.56×
1.39×
Q2 24
1.31×
0.80×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLDR
BLDR

Windows, doors & millwork$853.8M26%
Specialty building products & services$853.4M26%
Lumber & lumber sheet goods$845.4M26%
Manufactured products$734.5M22%

ZTS
ZTS

Companion Animal$1.5B67%
Livestock$720.0M32%
Contract Manufacturing & Human Health$23.0M1%

Related Comparisons